There is a sequence of steps to arrive at the following statement, "to access Sarepta’s PMOs or PPMOs for its competitive read-out study, PYC would need an MTA with Sarepta. Of course, one of the steps could be misspoken. It is however, also a logical deduction given the reference to outperformance compared with “the relevant competitive technology”.
My question.
Why would Sarepta give access to its PMOs under an MTA in order for Phylogica to use the data to begin and/or advance negotiations with competitor biotechs?
Of course the premise could be wrong and no MTA is in place. Perhaps it is possible to access a molecule under alternative scenarios as in the case with OmoMyc. Perhaps there is no intention to run competitive readouts with Sarepta's PMOs. If, however, an MTA is in place what are the commercial implications?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
-0.020(1.56%) |
Mkt cap ! $737.8M | |||
| Open | High | Low | Value | Volume |
| $1.29 | $1.29 | $1.25 | $4.616M | 3.649M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 19940 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.27 | 1008 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |